Skip to main
GUTS
GUTS logo

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is positioned favorably due to the significant surge in prescriptions for GLP-1 drugs, which have increased by 587% from 2019 to 2024, highlighting a growing market for metabolic treatments. The company's focus on developing disease-modifying therapies that address root causes of metabolic diseases aligns with this increased demand and indicates potential for substantial market penetration. Additionally, expectations of sufficient manufacturing efforts to support ongoing clinical trials suggest scalable capabilities that could enhance operational efficiency and future product delivery.

Bears say

Fractyl Health's financial outlook reveals concerns regarding its cash burn, particularly as the company increases its number of development and commercial programs, which could strain resources. Despite reporting a notable decrease in HbA1c levels from 9.6% to 7% over two years, the company's reliance on potential partner or collaborative milestone revenue remains uncertain. Additionally, while the reduction in fat mass is promising, the overall financial stability may be jeopardized without a clear path to sustainable revenue generation.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.